A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO) (ESSENCE)
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of Apremilast 30 mg Twice Daily in Chinese Subjects With Moderate to Severe Plaque-type Psoriasis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Amgen Call Center
- Phone Number: 866-572-6436
- Email: medinfo@amgen.com
Study Locations
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100191
- Peking University Third Hospital
-
Beijing, Beijing Municipality, China, 100034
- Peking University First Hospital
-
-
Fujian
-
Fuzhou, Fujian, China, 350000
- The First Affiliated Hospital of Fujian Medical University
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510091
- Dermatology Hospital of Southern Medical University
-
-
Hebei
-
Shijiazhuang, Hebei, China, 050000
- The Second Hospital of Hebei Medical University
-
-
Henan
-
Nanyang, Henan, China, 473002
- Nanyang First Peoples Hospital
-
-
Hubei
-
Yichang, Hubei, China, 443003
- Yichang Central Peoples Hospital
-
-
Hunan
-
Changsha, Hunan, China, 410011
- The Second Xiangya Hospital of Central South University
-
-
Jiangsu
-
Suzhou, Jiangsu, China, 215006
- Changshu No2 Peoples Hospital
-
Wuxi, Jiangsu, China, 241023
- Wuxi Peoples Hospital
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330000
- Dermatology Hospital of Jiangxi Province
-
-
Jilin
-
Changchun, Jilin, China, 130021
- The First Bethune Hospital of Jilin University
-
-
Ningxia
-
Yinchuan, Ningxia, China, 750003
- General Hospital of Ningxia Medical University
-
-
Shandong
-
Jinan, Shandong, China, 830001
- Shandong Provincial Hospital For Skin Diseases,Shandong First Medical University
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200443
- Shanghai Skin Disease Hospital
-
Shanghai, Shanghai Municipality, China, 200025
- Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
-
-
Sichuan
-
Chengdu, Sichuan, China, 610017
- Chengdu Second Peoples Hospital
-
Chongqing, Sichuan, China, 400010
- The Second Affiliated Hospital of Chongqing Medical University
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, China, 300052
- Tianjin Medical University General Hospital
-
-
Xinjiang
-
Ürümqi, Xinjiang, China, 830001
- Peoples Hospital of Xinjiang Uygur Autonomous Region
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310016
- Sir Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria
- Chinese participants aged ≥18.
- Diagnosis of chronic, stable moderate to severe plaque PsO for ≥ 12 months before screening. The participant must have sPGA score ≥ 3, PASI score ≥ 12, and BSA involvement ≥ 10% at both screening and baseline (week 0).
- Participant is a candidate for phototherapy and/or systemic therapy. Exclusion Criteria
- Psoriasis flare within 4 weeks of screening.
- Evidence of skin conditions that would interfere with evaluations of the effect of study medication on psoriasis.
- Prior medical history of suicide attempt at any time in the participant's lifetime before screening or randomization, or major psychiatric illness requiring hospitalization within the last 3 years.
- Participant has a malignancy or history of malignancy or myeloproliferative or lymphoproliferative disease within the past 3 years.
- Active tuberculosis or a history of incompletely treated tuberculosis.
- History of human immunodeficiency virus (HIV) infection.
- Prior treatment with apremilast.
- Female participants of childbearing potential unwilling to use protocol specified method of contraception.
- Female participants who are breastfeeding or who plan to breastfeed.
- Female participants planning to become pregnant.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Placebo-controlled Treatment Phas
Participants are randomized in a 1:1 ratio to take either apremilast or placebo BID for 16 weeks.
|
Oral tablet
Oral tablet
Other Names:
|
|
Experimental: Active Treatment Phase
Participants who received placebo during the placebo-controlled treatment phase will receive apremilast BID for 36 weeks.
Participants who took apremilast will continue receiving it BID for 36 weeks.
|
Oral tablet
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of Participants Achieving at least a 75% Reduction (Improvement) From Baseline in Psoriasis Area and Severity Index (PASI) at Week 16
Time Frame: Week 16
|
Week 16
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants Achieving a Static Physician's Global Assessment (sPGA) Score of Clear (0) or Almost Clear (1) and with ≥ 2-point Reduction From Baseline at Week 16
Time Frame: Baseline and Week 16
|
Baseline and Week 16
|
|
|
Number of Participants Achieving ≥ 4-point Reduction (Improvement) From Baseline in the Whole Body Itch Scale (NRS) Score at Week 16
Time Frame: Baseline and Week 16
|
Baseline and Week 16
|
|
|
Number of Participants with Baseline Scalp Physician's Globa Assesment (ScPGA) of ≥ 2 Achieving a Clear (0) or Almost Clear (1) ScPGA and with ≥ 2-point Reduction From Baseline and at Week 16
Time Frame: Baseline and Week 16
|
Baseline and Week 16
|
|
|
Percent Change of PASI From Baseline at Week 16
Time Frame: Baseline and Week 16
|
Baseline and Week 16
|
|
|
Percent Change From Baseline in Affected Body Surface Area (BSA) at Week 16
Time Frame: Baseline and Week 16
|
Baseline and Week 16
|
|
|
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16
Time Frame: Baseline and Week 16
|
Baseline and Week 16
|
|
|
Number of Participants who Have a Baseline Scalp Itch NRS ≥ 4 and Achieving ≥ 4-point Reduction (Improvement) From Baseline in Scalp Itch NRS at Week 16
Time Frame: Baseline and Week 16
|
Baseline and Week 16
|
|
|
Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
Time Frame: Baseline to Week 52
|
TEAEs are any event that occurred after the participant received study treatment.
Any clinically significant changes in vital signs, electrocardiograms, and clinical laboratory tests that occurred after study treatment administration were recorded as TEAEs.
|
Baseline to Week 52
|
|
Plasma Concentration of Apremilast
Time Frame: Baseline to Week 16
|
Baseline to Week 16
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: MD, Amgen
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases, Papulosquamous
- Skin Diseases
- Psoriasis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Inflammatory Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Sensory System Agents
- Analgesics, Non-Narcotic
- Analgesics
- Anti-Inflammatory Agents, Non-Steroidal
- Phosphodiesterase Inhibitors
- Phosphodiesterase 4 Inhibitors
- apremilast
Other Study ID Numbers
Other Study ID Numbers
- 20200250
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.